secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001654954-24-006233
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences reports Q1 net loss of $2.8M; advances TAEUS liver system with FDA and UK clinical study
--------------------------------------------------------------------------------

- Net loss of $2.8M ($0.26 per share) vs $2.9M ($0.93 per share) in Q1 2023; operating expenses $2.8M.
- Cash and cash equivalents were $1.1M as of March 31, 2024.
- First TAEUS system installed at King's College Hospital (UK) for a clinical study evaluating liver fat vs MRI (approx 75 subjects).
- FDA pre-submission meeting scheduled in Q2 2024 to align on clinical requirements for De Novo application.
- Expanded IP portfolio to 80 issued patents globally; exploring licensing for non-core indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424006233/0001654954-24-006233-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424006233/ndra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-006233

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer